“Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials”. SKIN The Journal of Cutaneous Medicine 9, no. 6 (November 10, 2025): s660. Accessed January 23, 2026. https://skin.dermsquared.com/skin/article/view/3833.